Comparison of Survival Outcomes Between Patients With Malignant Mixed Mullerian Tumors and High-Grade Endometrioid, Clear Cell, and Papillary Serous Endometrial Cancers

被引:46
作者
Felix, Ashley Sinclair [1 ,2 ]
Stone, Roslyn A. [3 ]
Bowser, Robert [6 ]
Chivukula, Mamatha [4 ]
Edwards, Robert P. [5 ]
Weissfeld, Joel L. [1 ,2 ]
Linkov, Faina [1 ,2 ]
机构
[1] Univ Pittsburgh, Inst Canc, Div Canc Prevent & Populat Sci, Pittsburgh, PA 15232 USA
[2] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15232 USA
[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15232 USA
[4] UPMC Hlth Syst, Magee Womens Hosp, Dept Pathol, Pittsburgh, PA USA
[5] UPMC Hlth Syst, Magee Womens Hosp, Dept Obstet & Gynecol Oncol, Pittsburgh, PA USA
[6] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15232 USA
基金
美国国家卫生研究院;
关键词
Mortality; Aggressive endometrial cancers; Carcinosarcoma; PROGNOSTIC-FACTORS; UTERINE CARCINOSARCOMA; METAPLASTIC CARCINOMAS; GYNECOLOGIC CANCER; ADJUVANT THERAPY; UTERUS; RECURRENCE; VARIABLES; PATTERNS;
D O I
10.1097/IGC.0b013e31821a62dd
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Malignant mixed mullerian tumors (MMMTs) are an aggressive subtype of endometrial cancer (EC). Previous studies compare survival between high-grade endometrioid (EM), clear cell (CC), and papillary serous (PS) ECs; yet few studies compare MMMTs to these aggressive subtypes. The goal of this study was to compare recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) among EC subtypes. Methods: We conducted a retrospective cohort study of EC cases treated at Magee-Women's Hospital between 1996 and 2008. Kaplan-Meier estimates of RFS, DSS, and OS as well as and log-rank tests were used to compare survival distributions between histologic subtypes. Cox regression was used to estimate hazard ratios for histologic subtypes, adjusted for other significant prognostic factors. Interactions between histologic subtype and prognostic factors were examined to assess effect modification. Results: This cohort included 81 MMMT (15%), 254 high-grade EM (46%), 73 CC (13%), and 147 PS (26%) cases. Compared to high-grade EM (6%) and CC (7%) cases, relatively more MMMT (12%) and PS (12%) cases were nonwhite. Stage differed significantly among the subtypes, with 36%, 34%, 37%, and 51% of MMMT, high-grade EM, CC, and PS cases, respectively, diagnosed at advanced late stage (P < 0.001). Kaplan-Meier curves and log-rank tests showed similar RFS, DSS, and OS between MMMT, high-grade EM, CC, and PS cases stratified by stage. In adjusted Cox regression models, RFS and DSS were not significantly different between MMMT and other subtypes. High-grade EM cases had a significantly better OS compared to MMMT cases (HR, 0.63; 95% confidence interval [CI], 0.41-0.98). Conclusions: This is the first retrospective study to suggest that certain survival outcomes are similar among MMMT, high-grade EM, CC, and PS subtypes. Other large-scale studies are needed to confirm these findings.
引用
收藏
页码:877 / 884
页数:8
相关论文
共 28 条
[11]   Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? [J].
McCluggage, WG .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (05) :321-325
[12]   Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas [J].
McCluggage, WG .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2002, 12 (06) :687-690
[13]   CLINICOPATHOLOGIC ANALYSIS OF UTERINE MALIGNANT MIXED MULLERIAN TUMORS [J].
NIELSEN, SN ;
PODRATZ, KC ;
SCHEITHAUER, BW ;
OBRIEN, PC .
GYNECOLOGIC ONCOLOGY, 1989, 34 (03) :372-378
[14]   An evaluation of prognostic factors in uterine carcinosarcoma [J].
Nordal, RR ;
Kristensen, GB ;
Stenwig, AE ;
Nesland, JM ;
Pettersen, EO ;
Trope, CG .
GYNECOLOGIC ONCOLOGY, 1997, 67 (03) :316-321
[15]   FIGO staging of gynecologic cancer [J].
Pecorelli, S ;
Benedet, JL ;
Creasman, WT ;
Shepherd, JH .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1999, 65 (03) :243-249
[16]   MANAGEMENT OF MALIGNANT, MIXED MESODERMAL TUMORS OF THE UTERUS [J].
PODCZASKI, ES ;
WOOMERT, CA ;
STEVENS, CW ;
MANETTA, A ;
LARSON, JE ;
ZAINO, RJ ;
MORTEL, R .
GYNECOLOGIC ONCOLOGY, 1989, 32 (02) :240-244
[17]   FIGO staging for uterine sarcomas [J].
Prat, Jaime .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2009, 104 (03) :177-178
[18]   Carcinosarcoma of the uterus: A clinicopathological multicenter CTF study [J].
Sartori, E ;
Bazzurini, L ;
Gadducci, A ;
Landoni, F ;
Lissoni, A ;
Maggino, T ;
Zola, P ;
LaFace, B .
GYNECOLOGIC ONCOLOGY, 1997, 67 (01) :70-75
[19]   PROGNOSTIC FACTORS FOR MALIGNANT MIXED MULLERIAN TUMORS OF THE UTERUS [J].
SCHWEIZER, W ;
DEMOPOULOS, R ;
BELLER, U ;
DUBIN, N .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1990, 9 (02) :129-136
[20]   CARCINOSARCOMA (MALIGNANT MIXED MESODERMAL TUMOR) OF THE UTERUS - A GYNECOLOGIC ONCOLOGY GROUP PATHOLOGICAL-STUDY OF 203 CASES [J].
SILVERBERG, SG ;
MAJOR, FJ ;
BLESSING, JA ;
FETTER, B ;
ASKIN, FB ;
LIAO, SY ;
MILLER, A .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1990, 9 (01) :1-19